Rhizen Pharma’s partnered asset Umbralisib gets US FDA accelerated nod for relapsed or…
Umbralisib is a novel, next generation, oral, once daily, inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Rhizen Pharmaceuticals
Rhizen Pharma gets USFDA approval for Phase I trials of COVID-19 drug
The initial study would evaluate single ascending doses of the RP7214 in healthy volunteers and that dosing is expected to…